Abstract: Aspects of the present disclosure include methods for treating at least one of insulin resistance, diabetes, and prediabetes, and, optionally, also non-alcoholic steatohepatitis (NASH). In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

Abstract: An implantable medical device comprises an electronics module comprising communication circuitry for at least one of transmitting communication signals to and receiving communication signals from an external communication device, and further comprising processing circuitry for at least one of processing sensed biological signals and generating stimulation signals for emission. An electrode arrangement serves for at least one of sensing said biological signals of a patient and emitting said stimulation signals. An electrical line extends in between the electronics module and the electrode arrangement, wherein the electrical line comprises a first line section, a second line section and a decoupling element, the first line section being electrically decoupled at RF frequencies from the second line section by the decoupling element and forming an antenna for at least one of transmitting and receiving said communication signals.

Abstract: Embodiments of the present technology include electroplating methods that include providing a first portion of an electrolyte feedstock to a first compartment of an electrochemical cell. The first portion of an electrolyte feedstock may be characterized by an initial metal ion concentration and an initial acid concentration. The methods may include providing a second portion of an electrolyte feedstock to a second compartment of the electrochemical cell. The second compartment and first compartment may be separated by a first membrane. The methods may include providing an acidic solution to a third compartment of the electrochemical cell. The third compartment and second compartment may be separated by a second membrane. The acidic solution may be characterized by an initial acid concentration. The methods may include applying a current to an anode of the electrochemical cell. The anode of the electrochemical cell may be disposed proximate the first compartment and across from the first membrane.

Abstract: Methods of treating alcoholic hepatitis (AH) are provided. For instance, the methods may comprise administering 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or a salt thereof.

Abstract: Described are techniques for infusing environmental data into a Computer-Aided Design (CAD) workspace. The techniques include replicating a physical area in a CAD workspace, where a static object of the physical area is replicated in the CAD workspace with a single set of coordinates, and where a dynamic object of the physical area is replicated in the CAD workspace with a range of coordinates representing movement. The techniques further include using the CAD workspace to enable relative sizing of a modeled object in the CAD workspace, where the relative sizing is relative to the single set of coordinates associated with the static object and the range of coordinates associated with the dynamic object.

Abstract: An implantable medical device comprises an electronics module comprising communication circuitry for at least one of transmitting communication signals to and receiving communication signals from an external communication device, and further comprising processing circuitry for at least one of processing sensed biological signals and generating stimulation signals for emission. An electrode arrangement serves for at least one of sensing said biological signals of a patient and emitting said stimulation signals. An electrical line extends in between the electronics module and the electrode arrangement, wherein the electrical line comprises a first line section, a second line section and a decoupling element, the first line section being electrically decoupled at RF frequencies from the second line section by the decoupling element and forming an antenna for at least one of transmitting and receiving said communication signals.

Abstract: Aspects of the present disclosure include methods for treating at least one inflammatory condition, such as at least one of dental pulp inflammation, periodontal disease, skin inflammation, psoriasis, ulcerative colitis, osteoarthritis, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome (IBS), Alzheimer's disease, Parkinson's disease, pancreatitis (acute and/or chronic), hepatitis (viral and/or non-viral), atherosclerosis, myocarditis, idiopathic pulmonary disorder (IPD), chronic obstructive pulmonary disorder (COPD), pneumonia, chronic inflammatory lung disease, bronchitis, asthma, chronic kidney disease (CKD), nephritis, sepsis, ankylosing spondylitis, diverticulitis, and fibromyalgia. In some cases, the at least one inflammatory condition is associated with Epstein-Ban virus infection.

Abstract: Light emitting diode display panels with an open loop amplifier resulting in better brightness accuracy and matching between multiple light emitting diode strings.

Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

Abstract: Electroplating methods may include providing an electrolyte feedstock comprising copper to a first compartment of an electrochemical cell. The methods may include providing an acidic solution to a second compartment of the electrochemical cell. The first compartment and second compartment may be separated by a membrane. The methods may include applying a current to an anode of the electrochemical cell. The anode of the electrochemical cell may be disposed proximate the first compartment and across from the membrane. The methods may include forming an anolyte and catholyte precursor.

Abstract: Embodiments of the present technology include electroplating methods that include providing a first portion of an electrolyte feedstock to a first compartment of an electrochemical cell. The first portion of an electrolyte feedstock may be characterized by an initial metal ion concentration and an initial acid concentration. The methods may include providing a second portion of an electrolyte feedstock to a second compartment of the electrochemical cell. The second compartment and first compartment may be separated by a first membrane. The methods may include providing an acidic solution to a third compartment of the electrochemical cell. The third compartment and second compartment may be separated by a second membrane. The acidic solution may be characterized by an initial acid concentration. The methods may include applying a current to an anode of the electrochemical cell. The anode of the electrochemical cell may be disposed proximate the first compartment and across from the first membrane.

Abstract: Aspects of the present disclosure include methods for treating at least one of insulin resistance, diabetes, and prediabetes, and, optionally, also non-alcoholic steatohepatitis (NASH). In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25- hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27- hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24- hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

Abstract: Exemplary methods of semiconductor processing may include performing an electroplating operation on a semiconductor substrate in an electroplating bath within a vessel of an electroplating system. The methods may include removing the semiconductor substrate from the electroplating bath. The methods may include closing a valve associated with a first drain from the electroplating system. The methods may include increasing flow to a second drain from the electroplating system. The second drain may be associated with a drain channel from the vessel of the electroplating system.

Abstract: Aspects of the present disclosure include methods for treating at least one of depression, neurodegenerative disease, multiple sclerosis, Parkinson's disease, spinocerebellar degeneration, Friedreich ataxia, ataxia-telangiectasia, progressive supranuclear palsy, Huntington's disease, striatonigral degeneration, olivopontocerebellar atrophy, Shy-Drager syndrome, schizophrenia, schizoaffective disorder, manic-depression (bipolar) disorder, disturbed or abnormal circadian entrainment, childhood Alice in Wonderland syndrome, childhood acute cerebellar ataxia, and Alzheimer's disease. In some instances, methods include treating an addiction to a drug, such as alcohol addiction, cocaine addiction or amphetamine addiction.

Abstract: Methods of treating non-alcoholic steatohepatitis (NASH) are provided. For instance, the methods comprise administering 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or a salt thereof.

Abstract: Methods of treating infectious diseases are provided. For instance, the methods may comprise administering at least one antimicrobial in combination with at least one oxygenated cholesterol sulfate (OCS). Methods for preventing and/or treating organ dysfunction and/or organ failure for patients with an infectious disease are described herein. Methods for preventing and/or treating tissue damage of one or more organs or organ systems for patients with an infectious disease are described herein.

Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

Abstract: Methods of treating alcoholic hepatitis (AH) are provided. For instance, the methods may comprise administering 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or a salt thereof.

Abstract: Aspects of the subject technology relate to control circuitry for light-emitting diodes. The control circuitry may include feedforward control and a feedback control for a power supply for the light-emitting diodes. The feedforward control may include host circuitry for the device that determines a maximum zone current, a maximum row current, and the maximum row-to-row current step for an upcoming backlight frame while a current backlight frame is being executed. A headroom voltage for the upcoming backlight frame is determined based on the maximum zone current, the maximum row current, and/or the maximum row-to-row current step and provided to the power supply so that the power supply can settle at a corresponding supply voltage before the upcoming backlight frame is executed. The feedback control utilizes dynamic thresholds determined for each backlight frame to fine tune the feedforward-determined headroom voltage.

Abstract: Aspects of the subject technology relate to an electronic device with a display. The display includes a first array of light-emitting diodes of a backlight unit to generate backlight for the display with each LED including an anode and a cathode. A first switch selectively couples a power supply voltage to a common anode of the first array of LEDs to control illumination of the first array of LEDs. A first discharge switch selectively couples a first voltage level to the common anode of the first array of LEDs to discharge the common anode to prevent an undesired current path through the first array of LEDs and associated undesired illumination.